Literature DB >> 11861971

A Physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model for the organophosphate insecticide chlorpyrifos in rats and humans.

C Timchalk1, R J Nolan, A L Mendrala, D A Dittenber, K A Brzak, J L Mattsson.   

Abstract

A PBPK/PD model was developed for the organophosphate insecticide chlorpyrifos (CPF) (O,O-diethyl-O-[3,5,6-trichloro-2-pyridyl]-phosphorothioate), and the major metabolites CPF-oxon and 3,5,6-trichloro-2-pyridinol (TCP) in rats and humans. This model integrates target tissue dosimetry and dynamic response (i.e., esterase inhibition) describing uptake, metabolism, and disposition of CPF, CPF-oxon, and TCP and the associated cholinesterase (ChE) inhibition kinetics in blood and tissues following acute and chronic oral and dermal exposure. To facilitate model development, single oral-dose pharmacokinetic studies were conducted in rats (0.5-100 mg/kg) and humans (0.5-2 mg/kg), and the kinetics of CPF, CPF-oxon, and TCP were determined, as well as the extent of blood (plasma/RBC) and brain (rats only) ChE inhibition. In blood, the concentration of analytes followed the order TCP >> CPF >> CPF-oxon; in humans CPF-oxon was not quantifiable. Simulations were compared against experimental data and previously published studies in rats and humans. The model was utilized to quantitatively compare dosimetry and dynamic response between rats and humans over a range of CPF doses. The time course of CPF and TCP in both species was linear over the dose range evaluated, and the model reasonably simulated the dose-dependent inhibition of plasma ChE, RBC acetylcholinesterase (AChE), and brain (rat only) AChE. Model simulations suggest that rats exhibit greater metabolism of CPF to CPF-oxon than humans do, and that the depletion of nontarget B-esterase is associated with a nonlinear, dose-dependent increase in CPF-oxon blood and brain concentration. This CPF PBPK/PD model quantitatively estimates target tissue dosimetry and AChE inhibition and is a strong framework for further organophosphate (OP) model development and for refining a biologically based risk assessment for exposure to CPF under a variety of scenarios.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11861971     DOI: 10.1093/toxsci/66.1.34

Source DB:  PubMed          Journal:  Toxicol Sci        ISSN: 1096-0929            Impact factor:   4.849


  51 in total

1.  Cytochrome P450-specific human PBPK/PD models for the organophosphorus pesticides: chlorpyrifos and parathion.

Authors:  Robert J Foxenberg; Corie A Ellison; James B Knaak; Changxing Ma; James R Olson
Journal:  Toxicology       Date:  2011-04-13       Impact factor: 4.221

Review 2.  Evaluation of epidemiology and animal data for risk assessment: chlorpyrifos developmental neurobehavioral outcomes.

Authors:  Abby A Li; Kimberly A Lowe; Laura J McIntosh; Pamela J Mink
Journal:  J Toxicol Environ Health B Crit Rev       Date:  2012       Impact factor: 6.393

3.  Longitudinal Assessment of Blood Cholinesterase Activities Over 2 Consecutive Years Among Latino Nonfarmworkers and Pesticide-Exposed Farmworkers in North Carolina.

Authors:  Sara A Quandt; Carey N Pope; Haiying Chen; Phillip Summers; Thomas A Arcury
Journal:  J Occup Environ Med       Date:  2015-08       Impact factor: 2.162

4.  Preliminary physiologically based pharmacokinetic models for benzo[a]pyrene and dibenzo[def,p]chrysene in rodents.

Authors:  Susan Ritger Crowell; Shantu G Amin; Kim A Anderson; Gowdahalli Krishnegowda; Arun K Sharma; Jolen J Soelberg; David E Williams; Richard A Corley
Journal:  Toxicol Appl Pharmacol       Date:  2011-09-29       Impact factor: 4.219

5.  Effect of CYP2B6*6 and CYP2C19*2 genotype on chlorpyrifos metabolism.

Authors:  Alice L Crane; Kathrin Klein; Ulrich M Zanger; James R Olson
Journal:  Toxicology       Date:  2012-01-18       Impact factor: 4.221

Review 6.  Development of translational pharmacokinetic-pharmacodynamic models.

Authors:  D E Mager; W J Jusko
Journal:  Clin Pharmacol Ther       Date:  2008-03-26       Impact factor: 6.875

7.  Reconstructing population exposures to environmental chemicals from biomarkers: challenges and opportunities.

Authors:  Panos G Georgopoulos; Alan F Sasso; Sastry S Isukapalli; Paul J Lioy; Daniel A Vallero; Miles Okino; Larry Reiter
Journal:  J Expo Sci Environ Epidemiol       Date:  2008-03-26       Impact factor: 5.563

Review 8.  Approaches for assessing risks to sensitive populations: lessons learned from evaluating risks in the pediatric population.

Authors:  Ronald N Hines; Dana Sargent; Herman Autrup; Linda S Birnbaum; Robert L Brent; Nancy G Doerrer; Elaine A Cohen Hubal; Daland R Juberg; Christian Laurent; Robert Luebke; Klaus Olejniczak; Christopher J Portier; William Slikker
Journal:  Toxicol Sci       Date:  2009-09-21       Impact factor: 4.849

Review 9.  Using physiologically-based pharmacokinetic-guided "body-on-a-chip" systems to predict mammalian response to drug and chemical exposure.

Authors:  Jong Hwan Sung; Balaji Srinivasan; Mandy Brigitte Esch; William T McLamb; Catia Bernabini; Michael L Shuler; James J Hickman
Journal:  Exp Biol Med (Maywood)       Date:  2014-06-20

10.  Interaction of the serine hydrolase KIAA1363 with organophosphorus agents: Evaluation of potency and kinetics.

Authors:  Matthew K Ross; Kim Pluta; Victoria Bittles; Abdolsamad Borazjani; J Allen Crow
Journal:  Arch Biochem Biophys       Date:  2015-11-23       Impact factor: 4.013

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.